Omnicomm Systems Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
14,331.80
16,461.30
20,710.80
25,419.50
26,979.70
27,104.50
Cost of Goods Sold (COGS) incl. D&A
9,504.00
11,916.40
4,721.70
5,715.10
5,639.00
5,638.50
Gross Income
4,827.80
4,544.90
15,989.10
19,704.50
21,340.60
21,466
SG&A Expense
5,304.80
6,400.20
14,736.90
15,445.10
17,915.20
18,852.20
EBIT
477.00
1,855.30
1,252.20
4,259.40
3,425.50
2,613.80
Unusual Expense
95.10
58.80
3,959.60
2,752.00
856.10
3,032.10
Non Operating Income/Expense
5.00
68.20
83.50
64.50
53.40
125.80
Interest Expense
2,490.10
2,614.20
2,733.80
1,339.90
1,367.10
1,342
Pretax Income
3,067.20
4,478.90
2,561.60
102.90
2,968.40
4,178.20
Income Tax
94.10
19.50
24.70
1.10
1.20
490.20
Consolidated Net Income
3,161.30
4,459.40
2,586.40
101.90
2,967.20
3,688
Net Income
3,161.30
4,459.40
2,586.40
101.90
2,967.20
3,688
Net Income After Extraordinaries
3,161.30
4,459.40
2,586.40
101.90
2,967.20
3,688
Net Income Available to Common
3,367.60
4,665.60
2,404.50
101.90
2,967.20
3,688
EPS (Basic)
0.04
0.05
0.02
0.00
0.02
0.02
Basic Shares Outstanding
87,969.20
90,701.10
96,645.50
145,868.20
147,865.20
150,832.50
EPS (Diluted)
0.04
0.05
0.02
0.00
0.02
0.02
Diluted Shares Outstanding
87,969.20
90,701.10
113,545.70
146,162.40
148,178.00
164,618.90
EBITDA
238.90
1,574.30
1,526.40
4,599.60
3,783.60
3,350.20
Non-Operating Interest Income
0.00
0.10
0.00
0.00
0.60
-
Preferred Dividends
206.30
206.30
181.90
-
-
-

About Omnicomm Systems

View Profile
Address
2101 West Commercial Boulevard
Fort Lauderdale Florida 33309
United States
Employees -
Website http://www.omnicomm.com
Updated 07/08/2019
OmniComm Systems, Inc. engages in the provision of software solutions in the field of sciences. It supports customers through innovative technologies in management of risks, regulatory compliance, and clinical operations in the field of pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers. Its products include 21 CFR Part 11 designed to offer clinical trial sponsors the ability to conduct clinical trials under multiple platforms.